Craig Chepke, MD, DFAPA

Blog

08/27/2021

Craig Chepke, MD, FAPA, discusses the stigma surrounding mental health disorders and how to change the view that mental health illness requires long-term treatment and care.

Craig Chepke, MD, FAPA,...

08/27/2021

Psych Congress Network

Preclinical Pharmacology of Solriamfetol: Potential Mechanisms for Wake Promotion

Abstract: Introduction: Solriamfetol is a wake-promoting agent (WPA) approved for the treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The...

Gregory Parks ;

Craig Chepke , MD, DFAPA;

01/25/2023

Safety and Efficacy of Low-Sodium Oxybate in Participants With Narcolepsy With and Without Psychiatric Comorbidities: Subgroup Analysis of a Phase 3 Clinical Trial

This study assessed safety and efficacy of low-sodium oxybate (LXB) in participants with narcolepsy both with and without comorbid psychiatric disorders in a phase 3 clinical study. Safet...

Craig Chepke , MD, DFAPA;

10/26/2023

Videos

Screening for ADHD via Telehealth

12/18/2023

Craig Chepke , MD, DFAPA;

Craig Chepke, MD, DFAPA, shares his thoughts on screening for, diagnosing, and treating ADHD via telehealth.

Craig Chepke, MD, DFAPA, shares...

12/18/2023

Psych Congress Network

Videos

Refining Your Treatment Options for Major Depressive Disorder (MDD)

08/16/2023

Craig Chepke , MD, DFAPA;

Craig Chepke, MD, DFAPA, gives an overview of the 4 antipsychotic adjunctive treatments approved for major depressive disorder.

Craig Chepke, MD, DFAPA, gives...

08/16/2023

Psych Congress Network

Why are clinicians wary of antipsychotic use in MDD treatment?

Expert Insights Quiz

Why do clinicians tend to underuse antipsychotics in the treatment of MDD?

07/27/2023

Craig Chepke , MD, DFAPA;

Time for a pop quiz!

07/27/2023

Psych Congress Network

Videos

Why Antipsychotics Are Underutilized for Major Depressive Disorder (MDD)

07/25/2023

Craig Chepke , MD, DFAPA;

Craig Chepke, MD, DFAPA, shares why he thinks clinicians do not use antipsychotics for MDD treatment as much as they could.

Craig Chepke, MD, DFAPA, shares...

07/25/2023

Psych Congress Network

Videos

Advancements in Tardive Dyskinesia Understanding and Management

10/01/2023

Craig Chepke , MD, DFAPA;

Craig Chepke, MD, DFAPA, discusses the latest advancements in the understanding of tardive dyskinesia and how clinicians can adapt their assessment and management strategies with this updated knowledge.

Craig Chepke, MD, DFAPA,...

10/01/2023

Psych Congress Network

Impact of Lemborexant on Patient-Reported Insomnia-Related Worry/Distress and Interference With Daily Functioning Over 6 Months: Results From SUNRISE-2

INTRODUCTION: The insomnia severity index (ISI) is a self-report instrument that evaluates perception of insomnia severity. In Study 303 (SUNRISE-2), lemborexant (LEM) showed greater red...

Rakesh Jain , MD, MPH, RD;

Jane Yardley , PhD;

Kate Pinner , MSc;

Manoj Malhotra , MD;

Margaret Moline , PhD;

Norman Atkins Jr., MBA, PhD;

Craig Chepke , MD, DFAPA;

10/08/2020

Effect of Lemborexant Treatment Across 12 Months on Fatigue Severity and Sleep Outcomes in Subjects With Clinically Significant Fatigue at Baseline

Introduction: The Fatigue Severity Scale (FSS) assesses impact of fatigue on patients’ lives. Lemborexant (LEM) efficacy was examined in the subgroup of subjects with baseline FSS total s...

Norman Atkins Jr., MBA, PhD;

Craig Chepke , MD, DFAPA;

Rakesh Jain , MD, MPH, RD;

Jane Yardley , PhD;

Manoj Malhotra , MD;

Kate Pinner , MSc;

Margaret Moline , PhD;

10/08/2020